Trials / Completed
CompletedNCT01628965
A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients
An Open-label Long-term Extension Trial From Phase II/III of SPM962 (243-07-001) in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 143 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Safety of SPM 962 in a once-daily repeated long-term treatment in Parkinson's disease patients who are not concomitantly treated with L-dopa will be investigated with a doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPM 962 | SPM 962 transdermal patch once a daily up to 36.0 mg/day |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2012-06-27
- Last updated
- 2014-03-19
- Results posted
- 2014-03-19
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01628965. Inclusion in this directory is not an endorsement.